CYP3A4 rs67666821: Understanding the CYP3A4*20 Variant
The rs67666821 variant, commonly referred to as the CYP3A4*20 allele, is a rare genetic change in the CYP3A4 gene. This variant is associated with a loss of function in the enzyme's ability to metabolize various clinically important medications.
What each genotype means
Reduced enzyme activity
This genotype indicates you carry one copy of the CYP3A4*20 allele, which is associated with reduced or non-functional enzyme activity. You may have an intermediate metabolizer phenotype, which could increase your susceptibility to side effects from drugs processed by this enzyme, such as certain pain medications or antibiotics. Please discuss your medication regimen and potential dosing adjustments with your clinician or pharmacist.
This genotype is rare, with the T allele occurring in less than 0.06% of individuals of European ancestry.
Significantly reduced enzyme activity
This genotype indicates you carry two copies of the CYP3A4*20 allele, which is associated with a loss of function in the CYP3A4 enzyme. Because this enzyme is responsible for metabolizing many common drugs, you may be at a higher risk for side effects or altered drug responses. It is important to share this information with your healthcare provider or pharmacist to ensure your medications are appropriate for your metabolism.
This genotype is extremely rare in the general population.
What is rs67666821?
The rs67666821 variant is a specific genetic marker located within the CYP3A4 gene on chromosome 7. In the context of pharmacogenomics, this single nucleotide polymorphism (SNP) is the defining marker for the CYP3A4*20 allele. While many genetic variants have little to no impact on health, rs67666821 is notable because it results in a nonfunctional protein. In standard genetic notation, the presence of the 'T' allele at this position indicates the presence of the *20 variant, whereas the absence of this allele is considered the common or reference form. Because this variant alters the structure of the resulting enzyme, it can significantly change how an individual's body processes certain substances, making it a subject of interest for researchers studying how genetics influence drug response.
The Role of the CYP3A4 Gene
The CYP3A4 gene provides instructions for making an enzyme called cytochrome P450 3A4. This enzyme is primarily found in the liver and the intestines, where it plays a critical role in the metabolism of a vast array of substances, including medications, toxins, and dietary components. CYP3A4 is responsible for breaking down more clinically used drugs than any other enzyme in the human body. By oxidizing these compounds, the enzyme generally inactivates them or prepares them for elimination from the body. Because of its central role in drug clearance, the activity level of CYP3A4 can determine the concentration of a drug in the bloodstream. When the gene is functioning normally, it ensures that medications are processed at an expected rate, but variations in the gene can lead to either faster or slower metabolism.
Research and Clinical Associations
Scientific research has identified the CYP3A4*20 allele as a loss-of-function variant, meaning individuals who carry this genetic change produce an enzyme that does not work as effectively as the standard version. Studies suggest that carriers of this variant may have an intermediate or poor metabolizer phenotype. This is clinically significant because if a patient is prescribed a drug that is normally broken down by CYP3A4, a reduced ability to metabolize that drug could lead to higher-than-intended levels of the medication in the body. This may increase the risk of side effects or adverse reactions. Research has specifically linked this variant to potential issues with common medications such as acetaminophen, codeine, and various other substrates. The evidence for this variant's impact is considered moderate, and it is recognized by pharmacogenomic databases as a key allele for clinical consideration.
Population Frequency
The rs67666821 variant is classified as rare across most human populations. Data indicates that the frequency of the T allele is very low, often cited as being less than 0.06% in Caucasian populations. Because the variant is so uncommon, the vast majority of the population carries the standard, functional version of the gene. While evolutionary studies suggest that the CYP3A locus has undergone selective sweeps in various populations, the specific *20 variant remains a rare finding in genetic testing. Its rarity means that it is not typically included in standard, broad-spectrum genetic screening panels unless specifically requested or indicated by a clinical pharmacogenomics program.
Navigating Genetic Information
Understanding your genetic profile regarding CYP3A4 can be a powerful tool, but it must be used in the right context. If you have received results indicating you carry the rs67666821 variant, it is important to remember that this information is only one piece of the puzzle regarding how your body responds to medication. Many factors, including age, liver function, diet, and other medications you may be taking, also influence drug metabolism. You cannot use this information to diagnose yourself or make changes to your prescribed treatments. If you are concerned about how your genetics might affect your response to a specific drug, you should discuss these results with your clinician or a pharmacist. They are best equipped to interpret these findings in the context of your overall health and current treatment plan.
How common is this variant?
The rs67666821 variant is rare, with the T allele occurring at a frequency of less than 0.06% in Caucasian populations.
Frequently asked questions
What does it mean to be a CYP3A4 metabolizer?
A metabolizer status describes how quickly your body breaks down drugs using the CYP3A4 enzyme. Normal metabolizers process drugs at a standard rate, while intermediate or poor metabolizers may process them more slowly, potentially leading to higher drug levels in the blood.
Should I get tested for rs67666821?
Genetic testing for specific variants like rs67666821 is usually only recommended if you are experiencing unexpected side effects from medications or if your doctor is planning a treatment that is highly sensitive to CYP3A4 activity. You should consult with your healthcare provider to determine if pharmacogenomic testing is appropriate for your medical history.
Can I change my CYP3A4 activity level?
While you cannot change your underlying genetics, your enzyme activity can be influenced by external factors like drug-drug interactions. Certain medications can inhibit or induce the activity of the CYP3A4 enzyme, effectively changing how you metabolize other drugs regardless of your genotype.
Is rs67666821 the same as CYP3A4*20?
Yes, rs67666821 is the specific SNP identifier used in databases to define the CYP3A4*20 allele. They refer to the same genetic variation.
Sources & further reading
Educational information only, last refreshed 10/7/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs67666821?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP3A4
This SNP is associated with the activity of the major drug-metabolizing enzyme CYP3A4.
The defining SNP for the CYP3A4*22 allele, which leads to significantly reduced metabolism of statins and immunosuppressants.
The CYP3A4*18 variant is significantly associated with the risk of anti-tuberculosis drug-induced hepatotoxicity, with effects modulated by pre-existing liver disease status.
Intronic CYP3A4 variant (CYP3A4*1G) associated with altered clearance and clinical response to tacrolimus, cyclosporine, and statins.
CYP3A4 regulatory variant influencing transcription levels and downstream drug metabolism for various antineoplastics and immunosuppressants.